Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
This is a non-randomized, phase II, open label study of Surufatinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.
Head and Neck Cancers - Salivary Gland
DRUG: Surufatinib
Objective Response Rate (ORR), up to 24 months
Disease Control Rate (DCRï¼‰, up to 24 months|Progress free survival (PFS), up to 24 months|Overall Survival (OS), up to 24 months
This is a non-randomized, phase II, open label study of Surufatinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.